Skyline Diagnostics

The partners are developing and optimizing an algorithm that assesses the likelihood of a patient's cancer progressing to metastasis.

The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.

The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.

Dutch molecular diagnostics company SkylineDx recently established a presence in Boston to bolster its outreach to the North American market.

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009.

This story was originally posted on June 22.

Pages

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.